作为癌症抗血管生成疗法的新兴免疫学方法

Mohammadreza Azimi, Mahdokht Sadat Manavi, Maral Afshinpour, Roya Khorram, Reza Vafadar, Fatemeh Rezaei-Tazangi, Danyal Arabzadeh, Sattar Arabzadeh, Nasim Ebrahimi, Amir Reza Aref
{"title":"作为癌症抗血管生成疗法的新兴免疫学方法","authors":"Mohammadreza Azimi, Mahdokht Sadat Manavi, Maral Afshinpour, Roya Khorram, Reza Vafadar, Fatemeh Rezaei-Tazangi, Danyal Arabzadeh, Sattar Arabzadeh, Nasim Ebrahimi, Amir Reza Aref","doi":"10.1007/s12094-024-03667-2","DOIUrl":null,"url":null,"abstract":"<p>Targeting tumor angiogenesis, the formation of new blood vessels supporting cancer growth and spread, has been an intense focus for therapy development. However, benefits from anti-angiogenic drugs like bevacizumab have been limited by resistance stemming from activation of compensatory pathways. Recent immunotherapy advances have sparked interest in novel immunologic approaches that can induce more durable vascular pruning and overcome limitations of existing angiogenesis inhibitors. This review comprehensively examines these emerging strategies, including modulating tumor-associated macrophages, therapeutic cancer vaccines, engineered nanobodies and T cells, anti-angiogenic cytokines/chemokines, and immunomodulatory drugs like thalidomide analogs. For each approach, the molecular mechanisms, preclinical/clinical data, and potential advantages over conventional drugs are discussed. Innovative therapeutic platforms like nanoparticle delivery systems are explored. Moreover, the importance of combining agents with distinct mechanisms to prevent resistance is evaluated. As tumors hijack angiogenesis for growth, harnessing the immune system’s specificity to disrupt this process represents a promising anti-cancer strategy covered by this review.</p>","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":"139 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Emerging immunologic approaches as cancer anti-angiogenic therapies\",\"authors\":\"Mohammadreza Azimi, Mahdokht Sadat Manavi, Maral Afshinpour, Roya Khorram, Reza Vafadar, Fatemeh Rezaei-Tazangi, Danyal Arabzadeh, Sattar Arabzadeh, Nasim Ebrahimi, Amir Reza Aref\",\"doi\":\"10.1007/s12094-024-03667-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Targeting tumor angiogenesis, the formation of new blood vessels supporting cancer growth and spread, has been an intense focus for therapy development. However, benefits from anti-angiogenic drugs like bevacizumab have been limited by resistance stemming from activation of compensatory pathways. Recent immunotherapy advances have sparked interest in novel immunologic approaches that can induce more durable vascular pruning and overcome limitations of existing angiogenesis inhibitors. This review comprehensively examines these emerging strategies, including modulating tumor-associated macrophages, therapeutic cancer vaccines, engineered nanobodies and T cells, anti-angiogenic cytokines/chemokines, and immunomodulatory drugs like thalidomide analogs. For each approach, the molecular mechanisms, preclinical/clinical data, and potential advantages over conventional drugs are discussed. Innovative therapeutic platforms like nanoparticle delivery systems are explored. Moreover, the importance of combining agents with distinct mechanisms to prevent resistance is evaluated. As tumors hijack angiogenesis for growth, harnessing the immune system’s specificity to disrupt this process represents a promising anti-cancer strategy covered by this review.</p>\",\"PeriodicalId\":10166,\"journal\":{\"name\":\"Clinical and Translational Oncology\",\"volume\":\"139 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Translational Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s12094-024-03667-2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12094-024-03667-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

针对肿瘤血管生成(支持癌症生长和扩散的新血管的形成)的治疗一直是治疗开发的重点。然而,贝伐珠单抗等抗血管生成药物的疗效因代偿途径的激活而产生的抗药性而受到限制。免疫疗法的最新进展激发了人们对新型免疫方法的兴趣,这种方法可以诱导更持久的血管修剪,并克服现有血管生成抑制剂的局限性。本综述全面探讨了这些新兴策略,包括调节肿瘤相关巨噬细胞、治疗性癌症疫苗、工程纳米抗体和 T 细胞、抗血管生成细胞因子/凝血因子以及沙利度胺类似物等免疫调节药物。本文讨论了每种方法的分子机制、临床前/临床数据以及与传统药物相比的潜在优势。还探讨了纳米颗粒给药系统等创新治疗平台。此外,还评估了结合具有不同机制的药物以防止耐药性的重要性。由于肿瘤会劫持血管生成来促进生长,因此利用免疫系统的特异性来破坏这一过程是本综述所涉及的一种前景广阔的抗癌策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Emerging immunologic approaches as cancer anti-angiogenic therapies

Emerging immunologic approaches as cancer anti-angiogenic therapies

Targeting tumor angiogenesis, the formation of new blood vessels supporting cancer growth and spread, has been an intense focus for therapy development. However, benefits from anti-angiogenic drugs like bevacizumab have been limited by resistance stemming from activation of compensatory pathways. Recent immunotherapy advances have sparked interest in novel immunologic approaches that can induce more durable vascular pruning and overcome limitations of existing angiogenesis inhibitors. This review comprehensively examines these emerging strategies, including modulating tumor-associated macrophages, therapeutic cancer vaccines, engineered nanobodies and T cells, anti-angiogenic cytokines/chemokines, and immunomodulatory drugs like thalidomide analogs. For each approach, the molecular mechanisms, preclinical/clinical data, and potential advantages over conventional drugs are discussed. Innovative therapeutic platforms like nanoparticle delivery systems are explored. Moreover, the importance of combining agents with distinct mechanisms to prevent resistance is evaluated. As tumors hijack angiogenesis for growth, harnessing the immune system’s specificity to disrupt this process represents a promising anti-cancer strategy covered by this review.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信